托伐普坦联合新活素治疗老年顽固性心力衰竭对患者运动耐量的影响  

Effect of Toraputan and Neovtin for Elderly Refractory Heart Failure on Exercise Tolerance in Patients

作　　者：董小伟[1] Dong Xiaowei(Department of Cardiovascular Medicine,The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan,471003,China)

机构地区：[1]河南科技大学第一附属医院心血管内科,河南洛阳471003

出　　处：《黑龙江医学》2024年第19期2337-2340,共4页Heilongjiang Medical Journal

摘　　要：目的:探究托伐普坦联合新活素治疗老年顽固性心力衰竭对患者运动耐量的影响。方法:选取2022年1月—2022年12月河南科技大学第一附属医院诊治的110例老年顽固性心衰患者作为研究对象,按随机数表法分为对照组及研究组,每组各55例。对照组施行新活素治疗,研究组施行托伐普坦联合新活素治疗。对比两组患者的疗效、心功能、血清指标及心肺运动试验指标。结果:治疗7 d后,研究组的总有效率高于对照组,差异有统计学意义(χ^(2)=4.274,P<0.05);治疗7 d后,两组患者左心室射血分数(LVEF)均上升,左心室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)均下降,研究组LVEF高于对照组,LVEDD及LVESD低于对照组,差异有统计学意义(t=4.935、4.339、2.708,P<0.05);治疗7 d后,两组患者N端B型脑钠肽前体(NT-pro BNP)、降钙素原(PCT)均下降,6 min步行试验(6 MWT)均上升,且研究组NT-pro BNP及PCT低于对照组,高于6 MWT,差异有统计学意义(t=9.370、7.596、3.370,P<0.05);治疗7 d后,两组患者心肺运动试验指标均升高,且研究组高于对照组,差异有统计学意义(t=4.753、5.668、2.669,P<0.05)。结论:托伐普坦联合新活素治疗老年顽固性心力衰竭,效果显著,可改善患者心功能,缓解心衰症状,提高运动耐量。Objective:To explore the effect of torvastan combined with neoactin on exercise tolerance in elderly patients with refractory heart failure.Methods:110 cases of elderly refractory heart failure treated in The First Affiliated Hospital of Henan University of Science and Technology from January to December 2022 were selected.They were divided into control group and study group with random number table method,with 55 cases in each group.Control group were treated with neovalin,and the study group were treated with tolvaptan and neovalin.The efficacy,cardiac function,serum index and cardiopulmonary exercise tests were evaluated between the two groups.Results:After 7 days of treatment,the total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(χ^(2)=4.274,P<0.05).After 7 days of treatment,left ventricular ejection fraction(LVEF)increased in both groups,while left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)decreased in both groups.LVEF in the study group was higher than that in the control group,while LVEDD and LVESD were lower than that in the control group.The difference was statistically significant(t=4.935,4.339,2.708;P<0.05).After 7 days of treatment,the N-terminal B-type brain natriuretic peptide precursor(NT-proBNP)and procalcitonin(PCT)in both groups decreased,and the 6-min walking test(6 MWT)increased,and the NT-proBNP and PCT in the study group were lower than those in the control group,and higher than 6 MWT.The difference was statistically significant(t=9.370,7.596,3.370;P<0.05).After 7 days of treatment,cardiopulmonary exercise test indexes increased in both groups,and the study group was higher than the control group,with statistically significant difference(t=4.753,5.668,2.669;P<0.05).Conclusion:Tolvaptan and neovolin treatment in treating elderly refractory heart failure can improve cardiac function,relieve heart failure symptoms,and improve exercise tolerance.

关 键 词：托伐普坦 新活素 老年 顽固性心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]